Shows how quality of life differs among CRSwNP phenotypes, suggesting new insights into their impact on patients.
SNOT-22 can be used to effectively assess QOL and differentiate between CRSwNP phenotypes, highlighting a greater burden in N-ERD patients. Biomarker analysis supports the distinct inflammatory profile of N-ERD.
No takes yet. Share an insight, caveat, or question.
López-Chacón et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: